March 18, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, announces the filing of the Company’s unaudited interim financial statements as of and for the three and six month periods ended January 31, 2025 (the “Financial Statements”), the management’s discussion and analysis (“MD&A”), and the certifications of the Chief Executive Officer and Chief Financial Officer (respectively, “CEO” and “CFO”) relating to the Financial Statements (collectively, the “Interim Filings”). The Interim Filings are available on the Company’s profile at www.sedarplus.ca.  

 

About Helix BioPharma

Helix BioPharma Corp. is an oncology company shaping a near future where today’s hard-to-treat cancers are made vincible by novel therapies that rise to the challenge. The Company innovates from strength to tackle cancer’s biggest, most urgent challenges with a diverse pipeline of drug candidates with great potential and a head start, honed into first- and best-in-class oncology medicines. Its pipeline is spearheaded by a clinical-stage proprietary technology platform of bio-conjugates that score with precision against prevalent CEACAM6-expressing solid tumors. Its lead candidate, Tumour Defence BreakerTM L-DOS47, is a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of common, hard-to-treat solid tumors, taking the brakes off anti-cancer immunity and delivering a game-changing assist to today’s front-running anti-cancer therapies. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC), with novel strategically designed bi-specific ADCs targeting CEACAM6 in discovery.

 

Helix is listed on the TSX under the symbol “HBP”, on OTC PINK under the symbol “HBPCD” and on FWB under the symbol “HBP0”. For more information, please visit: https://www.helixbiopharma.com/

 

For more information, please contact:

Helix BioPharma Corp.

Bay Adelaide Centre - North Tower

40 Temperance Street, Suite 2

Toronto, ON M5H 0B4

Tel: 604-428-7050

Jacek Antas, Director

corporate@helixbiopharma.com

Forward-Looking Statements and Risks and Uncertainties

 

This news release contains certain statements regarding Helix BioPharma Corp. that constitute forward-looking statements and information (collectively, “forward looking statements”) as defined by Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include statements regarding plans, goals, objectives, intentions and expectations with respect to the Company’s future business, operations, research and development, including the Company’s activities relating to its CEACAM6 platform, L-DOS47 and new asset transactions that Helix intends to close. Forward-looking statements can further be identified by the use of forward-looking terminology such as “will”, “plans”, “expects”, or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions “will”, “may”, “could”, or “should” occur or be achieved, or comparable terminology referring to future events or results.

 

Forward-looking statements are statements about the future and are inherently uncertain and are necessarily based upon a number of estimates and assumptions that are also uncertain. Although the Company believes that the expectations reflected in such forward- looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking statements are intended to provide information about management’s current plans and expectations regarding future operations and may not be appropriate for other purposes. Certain material factors, estimates or assumptions have been applied in making forward-looking statements in this news release. The Company’s actual results could differ materially from those anticipated in the forward-looking statements contained in this news release as a result of numerous known and unknown risks and uncertainties, including the risk factors discussed in the Company’s continuous disclosure record filed under the Company’s profile on SEDAR+ at www.sedarplus.ca from time to time. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix’s management on the date of this new release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required.

  

_________________